Transarterial Therapy for Colorectal Liver Metastases

Neal Bhutiani; Robert C G Martin 2nd

doi:10.1016/j.suc.2015.12.003

Transarterial Therapy for Colorectal Liver Metastases

Surg Clin North Am. 2016 Apr;96(2):369-91. doi: 10.1016/j.suc.2015.12.003.

Authors

Neal Bhutiani¹, Robert C G Martin 2nd²

Affiliations

¹ Division of Surgical Oncology, Department of Surgery, University of Louisville, Louisville, KY, USA.
² Division of Surgical Oncology, Department of Surgery, University of Louisville, Louisville, KY, USA; Division of Surgical Oncology, Upper Gastrointestinal and Hepato-Pancreatico-Biliary Clinic, 315 East Broadway, #311, Louisville, KY 40202, USA. Electronic address: Robert.Martin@louisville.edu.

PMID: 27017870
DOI: 10.1016/j.suc.2015.12.003

Abstract

Until recently, hepatic arterial therapies (HAT) had been used for colorectal liver metastases after failure of first-, second-, and third-line chemotherapies. HAT has gained greater acceptance in patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy. The current data demonstrate that HAT is a safe and effective option for preoperative downsizing, optimizing the time to surgery, limiting non-tumor-bearing liver toxicity, and improving overall survival after surgery in patients with colorectal liver-only metastases. The aim of this review is to present the current data for HAT in liver-only and liver-dominant colorectal liver metastases.

Keywords: Chemoembolization; Colorectal liver metastases; Drug-eluting beads (DEB); Hepatic arterial therapy (HAT); Hepatic artery infusion (HAI); Surgical resection; Yttrium-90.

Publication types

Review

MeSH terms

Antineoplastic Agents / administration & dosage*
Colorectal Neoplasms / pathology*
Combined Modality Therapy
Hepatic Artery*
Humans
Liver Neoplasms / drug therapy*
Liver Neoplasms / secondary*
Liver Neoplasms / therapy

Substances

Antineoplastic Agents